Index · Artikel · GlaxoSmithKline files for European approval of diabetes drug albiglutide

GlaxoSmithKline files for European approval of diabetes drug albiglutide

2013-03-07 7
   
Advertisement
résuméLONDON Britain's biggest drugmaker GlaxoSmithKline said on Thursday it had filed for European approval of its new once-weekly diabetes drug albiglutide, as tries to gain a foothold in a crowded market. Albiglutide, used to treat type 2 diabetes, belo
Advertisement

GlaxoSmithKline files for European approval of diabetes drug albiglutide


LONDON Britain's biggest drugmaker GlaxoSmithKline said on Thursday it had filed for European approval of its new once-weekly diabetes drug albiglutide, as tries to gain a foothold in a crowded market.

Albiglutide, used to treat type 2 diabetes, belongs to the same class of injectable GLP-1 medicines as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca's Amylin unit.

The drug has not yet been approved anywhere in the world, GSK said.

As a latecomer to the GLP-1 market, however, analysts believe albiglutide may struggle to generate major sales.

GSK made a similar submission in the United States in January for albiglutide, one of a number of new drugs the company hopes will revive its product portfolio.

(Reporting by Alice Baghdjian; Editing by Paul Sandle)

TOP

  • Day/
  • Week/
  • Original/
  • Recommand

Updated